Valeant misses on top and bottom line

In this video

Share

Valeant misses on top and bottom line

CNBC's Meg Tirrell breaks down Valeant Pharmaceuticals' quarterly numbers which reported EPS of $1.40 Adj. on revenues of $2.42 billion.
02:08
Tue, Aug 9 20166:08 AM EDT